BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240906T133000
DTEND;TZID=Europe/Vienna:20240906T143000
DTSTAMP:20260422T063200
CREATED:20240213T191555Z
LAST-MODIFIED:20240710T090914Z
UID:1291-1725629400-1725633000@esmit.eanm.org
SUMMARY:FDG-PET/CT in Breast Cancer
DESCRIPTION:Breast cancer is the most common cancer in women worldwide and it is still one of the leading causes of morbi-mortality\, therefore being a major concern. 2-[18F]FDG PET/CT is commonly used in the clinical management of patients with breast cancer\, with significant impact on clinical management. Currently\, there is robust evidence supporting the usefulness of 2-[18F]FDG PET/CT in the initial staging of patients with locally advanced and metastatic breast cancer\, in the early assessment of treatment response and in the early detection of recurrence. The first presentation of this webinar will summarize the recently published “Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer” which was endorsed by other relevant societies in the subject of breast cancer (ACR\, ESSO\, ESTRO\, EUSOBI/ESR\, and EUSOMA). Updated information to support the recommendations to perform 2-[18F]FDG PET/CT in no special type breast cancer in different clinical settings will be provided. Despite no special type breast cancer presenting high 2-[18F]FDG avidity\, other breast cancer subtypes seem to be better evaluated with other PET radiopharmaceuticals. Therefore\, the second presentation will address the potential role of [18F]FES\, [89Zr]Trastuzumab\, [18F]Sodium fluoride (NaF)\, [18F]Fluciclovine (FACBC)\, [89Zr]Pembrolizumab and FAPI-ligands in breast cancer. During this webinar we want to brainstorm about the role of PET/CT in the different subtypes and clinical scenarios of patients with breast cancer. The webinar will be enriched by interactive clinical case discussion\, aiming to resemble the challenges found in daily clinical practice. \n\n\n\nLearning Objectives:  \n\n\n\n\nGeneral aspects to avoid false positive and false negative findings on 2-[18F]FDG PET/CT.\n\n\n\nDiagnostic accuracy of 2-[18F]FDG PET/CT compared to conventional imaging modalities.\n\n\n\nRecommendations for performing 2-[18F]FDG PET/CT in the initial staging\, in assessing response to therapy and in assessing recurrence.\n\n\n\nAppropriate PET radiopharmaceuticals to better address each breast cancer subtype.\n\n\n\nSpecific characteristics\, physiological biodistribution\, advantages and disadvantages of PET radiopharmaceuticals used in breast cancer beyond 2-[18F]FDG.\n\n\n\nGeneral interpretation criteria to optimize the information provided in the final PET/CT report.\n\n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nLioe-Fee de Geus-OeiModeratorLeiden\, Netherlands \n\n\n\n\n\nSofia VazSpeakerLisbon\, Portugal \n\n\n\n\n\nLidija AntunovicSpeakerMilan\, Italy \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fdg-pet-ct-in-breast-cancer/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240920T133000
DTEND;TZID=Europe/Vienna:20240920T143000
DTSTAMP:20260422T063200
CREATED:20240213T192107Z
LAST-MODIFIED:20240731T083213Z
UID:1294-1726839000-1726842600@esmit.eanm.org
SUMMARY:Paediatric Nuclear Medicine in Nephro-Urology
DESCRIPTION:The webinar will cover the most relevant methodological aspects of nuclear medicine techniques in paediatric nephrourology\, with particular attention to the choice of the radiotracer\, the correct patient preparation\, and the acquisition protocol. Some typical cases will show the main points of image processing and results visualization. The clinical part will deal with hydronephrosis and hydroureteronephrosis\, spacing from typical pelvicureteral junction obstruction to obstructive megaureter\, and some complex malformations\, such as duplex kidneys. The selected cases will pinpoint the critical clues used in interpreting and reporting the scintigraphic studies and the integration of scintigraphic data with other imaging modalities (ultrasounds\, MRI\, etc.) in evaluating paediatric nephrourology patients. \n\n\n\nLearning Objectives: The aim of this course is to review the methodology and the main indications for scintigraphic studies in paediatric nephro-urology\, taking into accounts the more relevant and recent international guidelines and offering various examples taken from the current clinical practice. \n\n\n\nSuggested Readings:1. The SNMMI and EANM Procedural Guidelines for Diuresis Renography in Infants and Children2. EANM procedural recommendations for managing the paediatric patient diagnostic nuclear medicine \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDiego CecchinModeratorPadua\, Italy \n\n\n\n\n\nPietro ZucchettaSpeakerPadua\, Italy \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/paediatric-nuclear-medicine-in-nephro-urology/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240926T090000
DTEND;TZID=Europe/Vienna:20240927T170000
DTSTAMP:20260422T063200
CREATED:20240213T181746Z
LAST-MODIFIED:20240916T051241Z
UID:1240-1727341200-1727456400@esmit.eanm.org
SUMMARY:Quantification of MPI
DESCRIPTION:UEMS EACCME has granted the accreditation of 10\,5 CME credits for this event. \n\n\n\nThis course provides a comprehensive overview of nuclear medicine imaging of coronary artery disease. General aspects\, details of radiotracers utilised\, examination protocols and case examples of myocardial perfusion imaging (MPI) using PET and SPECT will be discussed at the event. The focus here will be on the quantification of data (e.g. abnormality scores\, myocardial blood flow\, myocardial flow reserve) collected from MPI. The event will allow for both lectures and discussions and will be an interactive event. Pitfalls and regulatory aspects will be covered as well in this course. \n\n\n\n\n\n\n\nSave yourself a seatRegistration closed. For last-minute sign up please contact esmit@eanm.org Closed\n\n\n\n\n\n\n\n\nTarget Audience\n\n\n\n\n\nThe target audience includes nuclear medicine physicians\, cardiologists\, internists and radiologists who want to deepen their knowledge in the field of imaging coronary artery disease.\n\n\n\n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\n\nGain a deep insight into nuclear medicine imaging of coronary artery disease.\n\n\n\nBecome familiar with radiopharmaceuticals\, camera systems\, examination protocols and regulatory aspects.\n\n\n\nTo learn SPECT\, PET image interpretation based on visual analysis and quantification.\n\n\n\nThe technique of absolute quantification of myocardial blood flow using PET or CZT cameras.\n\n\n\nAdditional value of hybrid imaging (SPECT/CT\, PET/CT and PET/MRI) in CAD.\n\n\n\nDiscussion of cases\, pearls and pitfalls.\n\n\n\n\n\n\n\n\n\n\nProgrammeClick to see the Preliminary Programme. Please note\, that it may be subject to change at any time. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nStephan  NekollaSpeakerTechnical University Munich\, Germany \n\n\n\n\n\nCarmela  NappiSpeakerUniversity of Naples Federico II\, Italy \n\n\n\n\n\nFederico  CaobelliSpeakerUniversitätsspital Bern\, Switzerland \n\n\n\n\n\nRaffaella  CalabrettaSpeakerMedizinische Universität Wien\, Austria \n\n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee Breaks on each Course Day\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation. \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/quantification-of-mpi/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:AI & Quantification,Onsite Course
END:VEVENT
END:VCALENDAR